A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Bruce E. Sands  ¹     Laurent Peyrin-Biroulet  ²     Silvio Danese  ³     David T. Rubin  ⁴     Severine Vermeire  ⁵     Christopher Ma  ⁶     Timothy Ritter  ⁷     Remo Panaccione  ⁸     Brian G. Feagan  ⁹     Dermot McGovern  ¹⁰     Olivier Laurent  ¹¹     Allison Luo  ¹¹     Deanna Nguyen  ¹¹     J. D. Lu  ¹¹     Anna Wiechowska-Kozlowska  ¹²     Jaroslaw Leszczyszyn  ¹³     Radoslaw Kempinski  ¹⁴     Jaroslaw Kierkus  ¹⁵     Stephan Targan  ^15    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² Inserm U954 and CHU de Nancy, Lorraine University, Nancy, France
³ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milano, Italy
⁴ University of Chicago Medicine, Chicago, United States
⁵ University Hospital Leuven, Leuven, Belgium
⁶ University of Calgary, Calgary, AB, Canada
⁷ GI Alliance, Southlake, United States
⁸ University of Calgary, Calgary, Canada
⁹ Western University, London, Canada
¹⁰ F. Widjaja IBD Institute, Cedars-Sinai Medical Center, Los Angeles, United States
¹¹ Prometheus Biosciences, Inc., San Diego, United States
¹² SONOMED Medical Center, Szczecin, Poland
¹³ Melita Medical Center, Wroclaw, Poland
¹⁴ Wroclaw Medical University, Wroclaw, Poland
¹⁵ Children’s Memorial Health Institute, Warsaw, Poland

Topic
Endoscopy, Histopathology, IBD

Session
The new kids on the block in IBD: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)